Melatonin

Clinical Summary

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous neurohormone synthesized from Tryptophan via Serotonin in the pineal gland, serving as the body's primary darkness signal and circadian phase marker. Exogenous melatonin at physiologic doses (0.3–3 mg) reduces sleep onset latency by 7–12 minutes (19 RCTs, N=1683, p<0.001) and advances circadian phase by 60–90 minutes when timed correctly.

Core value proposition: Cheap, safe, non-habit-forming, and genuinely effective for sleep onset and circadian disorders. The evidence is among the strongest for any supplement — 150+ PMIDs, 25+ meta-analyses, 584 registered clinical trials, and 3 EU-authorized pharmaceutical products.

Key clinical insight: Less is more. Ultra-low doses (0.3–0.5 mg) are as effective as 5 mg in head-to-head trials. Most commercial products are dosed 10–30× higher than the evidence-based optimum. Timing relative to circadian phase matters more than dose.

Who benefits most: Adults with sleep onset insomnia, delayed sleep phase syndrome (DSPS), jet lag (especially eastward), elderly with age-related melatonin decline, children with ASD/ADHD-related sleep onset delay, perioperative patients (anxiety and delirium prevention).

Who should be cautious: T2DM patients (may reduce insulin sensitivity), those on fluvoxamine (12–17× increase in melatonin levels) or warfarin, autoimmune conditions (theoretical immune enhancement). High-dose protocols (≥300 mg) with polypharmacy carry hepatotoxicity risk (PMID: 41706381).

Endogenous synthesis: Pineal gland via Tryptophan → 5-HTP → Serotonin → N-acetylserotonin → melatonin. Rate-limited by AANAT enzyme (50–100× increase in darkness). Cofactors: Vitamin-B6 (pyridoxal phosphate), SAMe. Nocturnal peak: 2–4 AM. Production declines 30–50% with age.

Indications & Evidence

Indication	Evidence	Type	BH	Safety	Effect Size	Population	Dose	Duration	Key PMID
Sleep onset insomnia	5/5	DC	8	MON	−7–12 min SOL (d=0.3)	Adults, N=1683	0.3–3 mg IR	Ongoing	23691095
Jet lag (eastward)	5/5	DC	7	--	50–70% symptom ↓	Travelers ≥5 TZ, N=474	0.5–5 mg dest bedtime	3–5 d	12076414
Delayed sleep phase (DSPS)	5/5	DC	8	--	60–90 min phase advance (d=0.81)	Adolescents+adults, N=500+	0.5–5 mg 4–6 h pre-bed	4–8 wk+	16295212
Age-related insomnia (55+)	5/5	DC	7	MON	19% ↑ sleep quality	Adults 55+, N=900+	2 mg PR	Ongoing	18036082
Pediatric ASD sleep onset	5/5	DC	7	MON	−38–51 min SOL, +53 min TST	Children 2–18, N=125+	1–10 mg titrated	Ongoing	29096778
REM sleep behavior disorder	4/5	PC	6	MON	60–80% improvement	PD/synucleinopathy, N=300+	3–12 mg	Ongoing	28516479
Preoperative anxiety	4/5	PC	7	--	≈ midazolam efficacy	Surgical, N=2319	3–10 mg 60–90 min pre-op	Single dose	33319916
Postop delirium prevention	4/5	PC	7	MON	RR 0.72; ≥5 mg: RR 0.52	Elderly surgical, N=2115	3–10 mg periop	3–7 d	41702325
Pediatric ADHD sleep onset	4/5	PC	6	MON	−15–30 min SOL	Children 6–18, N=200+	3–6 mg	Ongoing	—
Migraine prevention	3/5	UCC	5	--	30–40% frequency ↓	Chronic migraineurs, N=200+	3 mg bedtime	8–12 wk	41627537
Blood pressure (non-dippers)	3/5	UCC	5	--	SBP −2–5 mmHg	Hypertensive, N=400+	2–5 mg PR	4–8 wk	41515249
Atopic dermatitis (adjunctive)	3/5	UCC	5	--	SCORAD ↓, sleep ↑, QoL ↑	Adults+children	3–10 mg	4+ wk	41787942
Shift work sleep disorder	3/5	UCC	4	--	+30–45 min daytime sleep	Shift workers, N=300+	0.3–5 mg pre-day sleep	As needed	41841489
Cardiometabolic biomarkers	3/5	BC	5	MON	↓FBG, LDL, TC, CRP, IL-6	Mixed, 63 RCTs	3–10 mg	8–12 wk	41515249
CKD supportive care	3/5	BC	4	--	↓lipids, inflammation, oxidative stress	CKD, MA	3–5 mg	8+ wk	41727206
Bone density (menopausal)	2/5	BC	3	--	Possible BMD ↑ (confounded)	Postmenopausal, N=190+	3–5 mg	12+ wk	41693954
IBD adjunctive (remission)	2/5	ME	4	MON	↓CRP, calprotectin (animal+case)	IBD	3–6 mg	Ongoing	—
Cancer adjuvant (high-dose)	2/5	AHE	3	WARN	Preclinical anti-proliferative	Cancer	20–40 mg	Variable	28420185
Neuroprotection/antioxidant	2/5	ME	4	--	↑SOD, GPx; ↓ROS (preclinical)	Neurological	5–20 mg	Variable	—
Longevity/anti-aging	2/5	AHE	2	--	Animal lifespan extension only	—	Variable	Ongoing	—
Depression (primary)	1/5	NE	1	--	No benefit beyond placebo	MDD, multiple RCTs	—	—	—
Cognitive enhancement	1/5	NE	1	--	No direct nootropic effect	Healthy adults	—	—	—
Testosterone boosting	1/5	NE	0	--	No human evidence	—	—	—	—

Reading this table: Stars = evidence volume. Type = causal evidence relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS indication.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | ME=Mechanistic extrapolation | AHE=Animal→human | NE=No evidence BH: 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN Safety signal — see Safety section | AVOID Contraindicated Stars: 5/5 Multiple large RCTs+MA | 4/5 Several human RCTs | 3/5 Some human pilot | 2/5 Animal/very limited human | 1/5 None/debunked

Prescribing

Dosing Table

Population	Dose	Timing	Form	Notes
Adults (sleep onset)	0.3–3 mg	30–60 min before bed	IR	Start 0.5 mg; ↑ if no response after 1 wk. Higher doses NOT more effective
Adults (sleep maintenance)	2–5 mg	60–90 min before bed	PR	Mimics natural secretion; EU-approved (Circadin)
Adults (DSPS)	0.5–5 mg	4–6 h before desired bedtime	IR	Timing > dose. Phase advance, not sedation
Jet lag (eastward)	0.5–5 mg	At destination bedtime	IR or SL	Start day of arrival; continue 3–5 d. Morning light enhances
Elderly (55+)	2 mg PR	1–2 h before bed	PR	Reduced clearance (40–50%); start low. Fall risk: morning grogginess
Children ASD (2–18)	1–10 mg titrated	30–60 min before bed	Liquid/chewable	Start 1–3 mg (age 2–5), 2–5 mg (6–12), 3–6 mg (13+); ↑ q1–2 wk
Children ADHD (6–18)	3–6 mg	30–60 min before bed	IR	Helps sleep onset only; does NOT improve ADHD symptoms
Preoperative	3–10 mg	60–90 min pre-surgery	IR	Less cognitive impairment than midazolam
Delirium prevention	3–10 mg	Perioperative bedtime	IR	≥5 mg more effective (RR 0.52); evidence strongest in elderly
Athletes	3 mg	30–60 min before bed	IR	During heavy training/competition; avoid <8 h before events. NOT banned by WADA
CYP1A2 slow metabolizers	0.5–1 mg	Standard	IR	1F/1F genotype: 2–3× higher exposure; morning grogginess likely
CYP1A2 fast metabolizers	3–5 mg or PR	Standard	IR or PR	Rapid clearance; may need PR for overnight coverage
Fluvoxamine co-administration	0.3 mg max	Standard	IR	12–17× increase in melatonin levels
Oral contraceptive users	0.5–1 mg	Standard	IR	CYP1A2 inhibition → 2–3× higher levels
Hepatic impairment (moderate)	0.5–2 mg	Standard	IR	50% dose reduction; extended half-life
Hepatic impairment (severe)	0.3–1 mg	Standard	IR	2–3× increased bioavailability

Formulation Table

Form	Bioavailability	Onset	Duration	Best For	Cost/mo
Immediate-release (IR)	9–33%	20–60 min	2–4 h	Sleep onset, circadian shift, jet lag, first-line	$3–15
Prolonged-release (PR)	10–25%	90–180 min	6–8 h	Sleep maintenance, elderly, frequent awakenings	$20–40
Sublingual (SL)	20–40%	10–30 min	2–3 h	Acute needs, travelers, rapid onset	$15–30
Liquid	15–35%	15–45 min	2–4 h	Pediatric, dose titration, micro-dosing	$15–30
Soft gel capsule	25–35%	30–50 min	2–4 h	Poor tablet absorption, consistent dosing	$12–21
Transdermal patch	15–30%	2–4 h	8–12 h	Sleep maintenance, circadian stabilization	$30+

Absorption: Empty stomach optimal (Cmax ↑30–40%). Large meals delay absorption 60–90 min. pH-independent (stable pH 1–7). Extensive first-pass hepatic metabolism via CYP1A2 (70–80%) and CYP2C19 (10–20%).

Cycling: NOT required. Long-term studies (6–12 months) show sustained efficacy with no tolerance, no receptor regulation changes, and no suppression of endogenous production at physiologic doses. Use as-needed for jet lag/shift work; continuous for chronic indications.

Condition-Specific Protocols

Sleep Onset Insomnia Protocol

Evidence: 5/5 | PMID: 23691095, 15649737

Phase 1: Initiation (Week 1–2)

0.5 mg IR, 30–60 min before desired sleep time, empty stomach
Dim lights (<10 lux) 1–2 h before dosing; no screens after dosing
Goal: establish responsiveness (most people respond)

Phase 2: Optimization (Week 3–4)

Titrate: if no response at 0.5 mg, try 1 mg, then 3 mg max. Higher doses NOT more effective.
If 3 mg IR insufficient for overnight coverage → switch to 2 mg PR
If "works for 2 hours then wake up" → likely CYP1A2 fast metabolizer → PR formulation

Phase 3: Maintenance (Week 4+)

Continue effective dose indefinitely. No tolerance develops. No cycling needed.
Reassess annually. If ineffective, investigate external factors (stress, caffeine, screen time).

Stop criteria: Morning grogginess unresolved by dose reduction; glucose worsening in T2DM.

Delayed Sleep Phase Syndrome Protocol

Evidence: 5/5 | PMID: 16295212, 18041481

Phase 1: Phase Advance (Week 1–4)

0.5–3 mg IR, 4–6 hours before desired bedtime (NOT at bedtime)
Combine with morning bright light (10,000 lux, 30 min upon waking)
Goal: advance sleep onset by 60–90 min

Phase 2: Stabilization (Week 5–8)

Maintain same dose and timing. Consistent schedule critical.

Phase 3: Maintenance (indefinite)

Many patients require long-term use. No tolerance.
Light therapy may allow dose reduction over time.

Expected outcomes: Sleep onset advances 60–90 min (Cohen's d = 0.81). Full stabilization at 6–8 weeks. Key study: 5 mg at 6 PM advanced sleep onset 82 minutes (PMID: 16295212).

Postoperative Delirium Prevention Protocol

Evidence: 4/5 | PMID: 41702325, 41690769, 41602948

Protocol:

5–10 mg IR at bedtime, starting 1 night preoperatively
Continue 3–5 nights postoperatively
≥5 mg dose shows 48% delirium reduction (RR 0.52, p<0.001)
Advantage over benzodiazepines: no respiratory depression, better cognitive recovery
Ramelteon showed NO benefit in head-to-head meta-analysis — melatonin preferred
Also effective in ICU setting (PMID: 41602948)

Elderly Insomnia Protocol

Evidence: 5/5 | PMID: 18036082, 20712869

Protocol:

2 mg prolonged-release (Circadin), 1–2 h before bed
Start with 1 mg PR if concerned about grogginess; titrate to 2 mg
Assess fall risk (melatonin-related morning grogginess + baseline gait instability)
Benefits sustained over 6+ months without tolerance (PMID: 20712869, N=791)
Do NOT use >5 mg — no additional benefit, more side effects
Monitor: Fall risk assessment, drug interactions (polypharmacy common)

Safety

Interactions Table

Interactant	Severity	Mechanism	Effect	Management
Fluvoxamine	Major	CYP1A2 inhibition	↑ melatonin 12–17×	Avoid or reduce to 0.3 mg
Warfarin	Major	Potentiated anticoagulation	↑ bleeding risk	Monitor INR closely
Immunosuppressants	Major	Immune enhancement	↓ immunosuppression efficacy	Use with caution; monitor levels
CNS depressants	Major	Additive sedation	Excessive drowsiness	Reduce doses of both
Antidiabetic medications	Major	↓ insulin sensitivity	Potential glucose worsening	Monitor glucose closely
Beta-blockers	Moderate	↓ endogenous melatonin + additive BP lowering	Hypotension, orthostasis	Monitor BP
Anticonvulsants	Moderate	CYP induction (carbamazepine, phenytoin)	↓ melatonin levels	May need 3–5 mg dose
Oral contraceptives	Moderate	CYP1A2 inhibition	↑ melatonin 2–3×	Start with 0.5–1 mg
SSRIs/SNRIs	Moderate	Variable CYP; serotonin modulation	Mild ↑ melatonin	Monitor drowsiness
Apatinib	Moderate	CYP1A2 inhibition	↑ melatonin AUC 2.8×	Reduce melatonin dose (PMID: 41825755)
CBD	Moderate	Bidirectional PEPT1/CYP1A2	Variable melatonin PK	Monitor effects (PMID: 41599679)
NSAIDs	Minor	↓ melatonin synthesis	Minimal clinical impact	No adjustment needed
Caffeine	Minor	Competitive CYP1A2 + adenosine antagonism	↓ efficacy 30–50%	Avoid caffeine 6+ h before melatonin
Alcohol	Minor	Disrupts sleep architecture; ↓ endogenous synthesis	Negates sleep quality benefits	Avoid within 3 h
Nicotine/smoking	Minor	CYP1A2 induction	↓ levels ~40%	Smokers may need higher dose

Contraindications

Absolute:

Pregnancy (insufficient safety data; crosses placenta)
Lactation (passes into breast milk; insufficient data)

Relative:

Severe autoimmune flare (theoretical immune enhancement)
Severe hepatic impairment at high doses (MELATOMS-1 hepatotoxicity signal)
Seizure disorders (rare reports of threshold lowering)
Severe dementia with sundowning (may worsen agitation)

Adverse Effects

Side Effect	Incidence	Dose-Dependent	Management
Daytime drowsiness	5–15%	Yes	Reduce dose; take earlier; ensure 8+ h sleep opportunity
Headache	3–8%	Variable	Usually resolves 1–2 wk; reduce dose if persistent
Dizziness	3–5%	Yes	Take with food; rise slowly
Nausea	2–5%	Yes	Take with light snack; reduce dose
Vivid dreams/nightmares	2–5%	Yes	Reduce dose; more common >3 mg
Morning grogginess	2–5%	Yes	Switch to IR from PR; take earlier; reduce dose
Mood changes (irritability)	<1%	Variable	Discontinue if persistent
Hypothermia	Rare	Yes	Excessive body temp reduction at high doses
Confusion/disorientation	Rare	—	Primarily elderly; discontinue immediately

Safety profile: Very wide therapeutic index. No deaths from overdose. Doses up to 300 mg used in research (though hepatotoxicity in polymedicated patients — PMID: 41706381). No physical dependence, no tolerance, no rebound insomnia. No suppression of endogenous production at physiologic doses.

FAERS Signal Table (from BioMCP)

Reaction	FAERS Reports	Suspect Drug?	Seriousness	Linked Indication	Notes
Fatigue	4,360	Mostly concomitant	Variable	Sleep disorders	Dominated by polypharmacy reports
Nausea	3,740	Mostly concomitant	Mild	—	Not a primary melatonin signal
Drug ineffective	3,160	Yes	N/A	All	Expected for OTC supplement — #1 melatonin-specific signal
Headache	2,922	Mixed	Mild	—	Plausible but inflated by concomitant use
Insomnia	2,543	Mostly concomitant	Moderate	Sleep	Paradoxical — likely the underlying condition
Dizziness	2,335	Plausible suspect	Mild	—	Consistent with known AE profile
Fall	2,375	Mostly concomitant	Serious	Elderly sleep	Polypharmacy/elderly population noise

FAERS context: Melatonin FAERS data is dominated by concomitant-medication reports (melatonin co-administered while another drug is the primary suspect). No novel safety signals detected beyond known AE profile. "Drug ineffective" is the most clinically meaningful melatonin-specific signal. Per FAERS supplement noise principle, raw counts are heavily inflated by polypharmacy reporting.

Monitoring Table

Test	When	Target	Population
Fasting glucose / HbA1c	Baseline, q3mo	No worsening	T2DM patients only
INR	Weekly initial, then routine	Therapeutic range	Warfarin users
Fall risk assessment	Baseline, q3mo	No new falls	Elderly (65+)
Sleep diary/actigraphy	Baseline, 4 wk, 12 wk	SOL <30 min, TST ≥7 h	All
Disease activity markers	Per protocol	No worsening	Autoimmune patients
LFTs (AST/ALT)	Baseline, q4wk	Normal	High-dose (>50 mg) + polypharmacy only

Special Populations

Hepatic Impairment

Severity	Dose Adjustment	Rationale	Evidence
Child-Pugh A (mild)	Standard or slight reduction (1–3 mg)	Reduced first-pass → ↑ bioavailability	PK studies
Child-Pugh B (moderate)	50% reduction (0.5–2 mg)	Extended half-life	PK extrapolation
Child-Pugh C (severe)	Ultra-low (0.3–1 mg)	2–3× ↑ bioavailability	PK extrapolation

Critical safety signal: MELATOMS-1 trial (PMID: 41706381) — 300 mg/day melatonin + ocrelizumab in progressive MS: 3/4 participants (all women on polypharmacy) developed grade 1–2 hypertransaminasemia. CYP450 pathway saturation from drug-drug interactions (acetaminophen, omeprazole, ibuprofen, tizanidine). Does NOT change safety profile at standard doses (0.3–10 mg). Relevance: high-dose protocols in polymedicated patients warrant LFT monitoring.

Renal Impairment

GFR Range	Dose Adjustment	Rationale	Evidence
60–89 (mild)	Standard	Hepatic metabolism, not renal	PK studies
30–59 (moderate)	Standard; monitor drowsiness	Metabolite accumulation possible	Limited data
<30 (severe)/ESRD	Start 0.5–1 mg	Metabolites may accumulate	Limited data; safe in dialysis

Pregnancy & Lactation

Pregnancy: No controlled trials. Animal data: no teratogenicity at 200 mg/kg. Maternal melatonin increases physiologically in 3rd trimester. Crosses placenta — potential effects on fetal circadian development unknown. Avoid unless severe insomnia under OB-GYN supervision. Phase 3 trial of antenatal neuroprotection in FGR underway (NCT05651347, N=336). Alternative: Magnesium-Glycinate (better pregnancy safety profile).
Lactation: Passes into breast milk (physiologically normal). No data on exogenous supplementation safety. Avoid. Optimize sleep hygiene and light exposure instead.

Pediatric Considerations

Infants (0–2): NOT recommended. Circadian system developing; insufficient data.
Young children (2–6): Only for neurodevelopmental disorders with severe sleep disturbance. Dose 0.5–3 mg. Monitor growth/pubertal development.
European pediatric guidance (2024): Low-dose, 30–60 min before bedtime, when behavioral therapies fail (PMID: 38625388).
Long-term safety: No evidence of effects on growth, BMI, or pubertal timing in studies up to 12 months. Longer data urgently needed.
Formulation preference: Liquid (ages 2–6), chewable (4–10), standard tablet (10+). Ensure third-party tested product — Erland 2017 quality concerns especially relevant for pediatric use.
ASD-specific: Strongest pediatric indication (5/5). 1–10 mg titrated. Sleep onset 38–51 min earlier, TST +53 min (PMID: 29096778).

Cardiovascular Disease

May modestly reduce BP (3–5 mmHg systolic), improve nocturnal "dipping" pattern
Safe in heart failure, arrhythmias, post-MI. No pro-arrhythmic effects
Use cautiously with orthostatic hypotension. May potentiate antihypertensives (modest additive effect)

Autoimmune Conditions

General: Current evidence suggests melatonin is generally safe in autoimmune diseases, with primary benefits for sleep. Theoretical immune-enhancing effects have NOT translated to clinical disease worsening in most conditions. Use with monitoring; discontinue if disease activity increases.
IBD: 3–10 mg adjunctive; potent gut mucosal antioxidant. Animal models + small human case series show benefit. Some evidence of worsening in certain patients — monitor.
RA: 3–5 mg for sleep; safe with DMARDs, NSAIDs, biologics. No disease-modifying effect.
SLE: Use cautiously; monitor anti-dsDNA, complement. No reports of flares triggered by melatonin.
Hashimoto's: Safe. No interaction with levothyroxine. Space 4 h for consistency.
MS: 3–5 mg for sleep/fatigue. High-dose (300 mg) hepatotoxic in MELATOMS-1 (polypharmacy context).

Synergies & Stacking

Co-nutrient	Mechanism	Evidence	Protocol
Magnesium-Glycinate	GABA potentiation, muscle relaxation, complementary sleep pathways	5/5	200–400 mg + melatonin 0.5–3 mg, 30–60 min before bed
Glycine	↓ core body temperature, ↑ sleep depth	4/5	3 g + melatonin 1–3 mg
L Theanine	Anxiolytic, ↑ alpha waves, GABA modulation	4/5	100–200 mg + melatonin 0.5–3 mg
Tryptophan / 5-HTP	Precursor for endogenous melatonin synthesis	3/5	May reduce exogenous melatonin need
Vitamin-B6	Cofactor for melatonin synthesis pathway	3/5	10–25 mg; may enhance dream vividness
GABA	Direct GABAergic synergy	2/5	250–500 mg; limited evidence

Evidence-based sleep stack:

Melatonin 0.5–3 mg IR + Magnesium-Glycinate 300 mg + Glycine 3 g + L Theanine 200 mg
Timing: 30–60 min before bed. This is the most widely validated sleep supplement protocol.

Antagonists: Caffeine (avoid 6+ h; ↓ efficacy 30–50%), alcohol (avoid 3 h; disrupts architecture), blue light (avoid screens 1–2 h post-dose), nicotine (CYP1A2 induction; ↓ levels ~40%).

Individual Response Modifiers

Sex-Specific Considerations

Factor	Male	Female	Clinical Implication
CYP1A2 activity	Baseline reference	~20–40% lower (higher melatonin exposure)	Women may respond to lower doses
Oral contraceptive use	N/A	CYP1A2 inhibition → 2–3× ↑ melatonin	Start 0.5–1 mg if on OC
Menopause	N/A	Climacteric symptoms improved by 0.3 mg (PMID: 41841489)	Low-dose melatonin has dual sleep+menopause benefit
MELATOMS-1 hepatotoxicity	1 male participant, no liver issues	3 females, all developed hypertransaminasemia	Possible sex difference in high-dose safety (confounded by polypharmacy)
AANAT polymorphism (rs4238989)	G allele → ↑ MDD risk in young males	No association	Screen young males with depression + sleep issues (PMID: 41789583)
Bone density	Less relevant	Low melatonin correlates with low BMD postmenopause	Consider melatonin if postmenopausal with osteopenia (PMID: 41883562)
Pregnancy/lactation	N/A	Avoid supplementation; insufficient safety data	See Special Populations
Study population bias	Most sleep RCTs include both sexes	Shift worker RCT (PMID: 41841489) was female-only	Key exercise RCTs predominantly male

Genetic Modifiers

Gene (SNP)	Variant	Effect on Melatonin	Evidence	Action
CYP1A2 (*1F)	1F/1F (slow)	2–3× higher exposure, longer half-life	Replicated	Start 0.5–1 mg; grogginess likely at standard doses
CYP1A2 (*1A)	1A/1A (fast)	Rapid clearance, shorter duration	Replicated	May need 3–5 mg or PR formulation
MTNR1B (rs10830963)	G allele (risk)	Stage-specific T2DM risk; altered beta-cell response	GWAS + iPSC modeling	G-carriers with T2DM: monitor glucose closely; melatonin may worsen insulin sensitivity
MTNR1B (rs10830963)	G allele	↑ gestational diabetes risk	Replicated multi-population	Pregnant G-carriers: avoid melatonin supplementation
AANAT (rs4238989)	G allele	↑ MDD risk in young males only	Single study (Chinese)	Young males with MDD: melatonin may not address underlying AANAT dysfunction
MTNR1A/MTNR1B	Various	Shift work + polymorphisms → hyperhomocysteinemia	Observational	Retired shift workers: check homocysteine (PMID: 41193358)

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent.

Dominant Sentiment

Polarized across ~15,000+ reports. Drugs.com: 46% positive, 36% negative. Reddit/biohacker communities: strong micro-dose advocacy camp (0.3 mg) vs smaller high-dose longevity camp (20–100+ mg). Dominant educated narrative: "it works but you're probably doing it wrong" — dosing too high, timing poorly.

What Users Report

Reported Effect	Frequency	Typical Onset	Source Communities
Faster sleep onset	Very common	20–60 min	All
Vivid dreams	Common (~20–30%)	First few nights	Reddit, Drugs.com
Morning grogginess ("hangover")	Common (~20%)	Next morning	Reddit, Drugs.com — #1 complaint
Nightmares	Moderately common	First nights; often resolves	Reddit
Waking at 1–3 AM	Common complaint	Variable	r/sleep, parent communities
Headaches	Occasional	Variable	Drugs.com
Nausea/dizziness	Occasional	Within hours	Drugs.com
Improved sleep quality (low doses)	Common	First week	r/biohackers
Reduced sleep quality (high doses)	Moderately reported	After initial days	r/nootropics, LongeCity
Constipation/slowed digestion	Occasional	Days of use	Health forums

Community Dosing vs Clinical

Source	Dose	Notes
US store shelves	3–10 mg	Likely 10–30× too high
Reddit/biohacker consensus	0.3–0.5 mg	"Less is more" — aligned with evidence
LongeCity longevity camp	20–100+ mg	Thin evidence; emerging cardiovascular concern
Huberman recommendation	0.1–0.3 mg (if at all)	Prefers mag threonate + theanine + apigenin
EU regulation	>2 mg = prescription	Regulated as pharmaceutical
Japan/Korea	Prescription or restricted	Japan OTC ≤2 mg from 2026

Popular Stacks (Community)

Stack	Purpose	Evidence Level
Melatonin 0.3–1 mg + Magnesium-Glycinate 200 mg + L Theanine 200 mg	Standard sleep stack	4/5
Melatonin + Magnesium Threonate + Apigenin	Huberman-adjacent sleep stack	3/5
Melatonin + Glycine 3 g	Sleep quality + morning clarity	4/5
High-dose melatonin (20 mg+) + Vitamin C + Zinc	Longevity/anti-cancer	1/5

Red Flags & Skepticism Notes

MLM involvement: None. Melatonin is too cheap and generic for MLM models.
Influencer concentration: Moderate. Andrew Huberman's skeptical stance has shifted biohacker discourse toward alternatives. Life Extension Foundation promotes high-dose protocols. These two camps define the polarization.
Astroturfing signals: Low for melatonin. However, "melatonin alternative" branded sleep stacks show clear affiliate marketing pipelines.
Commercial bias: Bidirectional. Supplement retailers incentivized to promote high-dose (higher margins). Branded alternative sellers incentivized to disparage melatonin.
Quality concerns (validated): Erland 2017 (PMID: 27855744): −83% to +478% of label; 26% contained undisclosed serotonin. Single most validated folk concern. USP/NSF verification matters.

Folk vs Clinical Reality Check

Community experience strongly validates the micro-dose paradigm (0.3 mg ≈ 5 mg), dose-dependent grogginess, and product quality concerns. Key divergences: (1) "tolerance/dependence" reports are not pharmacologically supported — likely receptor desensitization at supraphysiological doses or product quality variation; (2) high-dose longevity claims (20–100+ mg) extrapolate far beyond evidence; (3) melatonin consistently "fails" for sleep maintenance — clinically expected, as it is a circadian signal, not a sedative.

Deep Dive: Mechanisms & Research

Circadian regulation: Melatonin acts as the body's darkness signal via MT1/MT2 receptors in the suprachiasmatic nucleus (SCN), synchronizing peripheral tissue clocks. Phase-shifting depends on timing: evening doses advance phase (shift earlier), morning doses delay phase. SCN receives light input from melanopsin-containing retinal ganglion cells; blue light (460–480 nm) suppresses AANAT and melatonin synthesis.

Sleep induction: Reduces core body temperature by 0.2–0.4°C via peripheral vasodilation. Increases sleep propensity without direct sedation. Potentiates GABAergic neurotransmission. Does NOT suppress REM or deep sleep (unlike benzodiazepines). May increase REM sleep percentage and sleep spindles in elderly.

Antioxidant: Direct free radical scavenger (hydroxyl radicals, peroxynitrite, singlet oxygen). Upregulates SOD, glutathione peroxidase, catalase. Crosses BBB readily. Emerging roles in pyroptosis regulation (PMID: 41915594) and ferroptosis modulation (PMID: 41643263). Strong preclinical data, poor clinical translation at oral sleep doses.

Cardiometabolic (2025–2026): Landmark 63-RCT dose-response meta-analysis (PMID: 41515249): significant ↓ SBP (−2.3 mmHg), FBG (−11.6 mg/dL), LDL (−6.3 mg/dL), TC (−7.0 mg/dL), CRP (−0.59 mg/L), TNF-α (−1.6 pg/mL), IL-6 (−6.4 pg/mL), MDA (−1.5 µmol/L). ↑ HDL (+2.0 mg/dL), TAC (+0.15 mmol/L). NO effect on DBP, BMI, fasting insulin, HOMA-IR, HbA1c, or triglycerides. Biomarker improvement ≠ hard outcomes.

Delirium prevention (2025–2026): Three independent meta-analyses converge. PMID 41702325: 16 RCTs (N=2115), RR 0.72 (p=0.009); ≥5 mg: RR 0.52 (p<0.001). Ramelteon: NO benefit. BMJ NMA (PMID: 41690769) confirmed. ICU-specific benefit (PMID: 41602948). This is the most significant new clinical development.

Dermatology (2026): Atopic dermatitis RCT (PMID: 41787942): 80 patients, 10 mg × 4 wk → significant SCORAD improvement, pruritus reduction, QoL improvement. Confirmed in pediatric AD meta-analysis (PMID: 41647028). Topical melatonin has moderate evidence for hair growth in androgenetic alopecia.

Metabolic/genetic: MTNR1B rs10830963 is a validated T2DM risk locus with stage-specific effects across the disease trajectory (PMID: 40869173). Successfully modeled in iPSC beta cells (PMID: 40898610). Associated with gestational diabetes in multiple populations.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

NCT ID	Title	Phase	Status	Conditions	N
NCT06802913	Inhaled melatonin 100µg vs oral 4mg	Early Ph1	Recruiting	Insomnia	10
NCT05541276	Emergence delirium in children	Ph3	Recruiting	Pediatric delirium	400
NCT06859957	Chronic low-back pain	Ph3	Recruiting	Pain	240
NCT05084196	AKI prevention	Ph3	Recruiting	Renal	300
NCT05651347	Antenatal neuroprotection in FGR	Ph3	Recruiting	Fetal/neonatal	336
NCT05502900	Adjuvant for uveal melanoma	Ph3	Recruiting	Oncology	100
NCT06226025	Bipolar + DSWPD circadian correction	Ph2	Recruiting	Psychiatry	50
NCT03954899	Disease-modifying potential in MCI	NA	Recruiting	Cognitive decline	—

584 total registered trials. 298 completed. 58 currently recruiting. Broadest activity in: delirium prevention, pediatric sleep, neuroprotection, oncology adjuvant, pain management.

Regulatory Status

FDA: No drug approval. Sold as dietary supplement under DSHEA (1994). Not regulated as drug.
EMA: Authorized. Circadin (2 mg PR, adults 55+, insomnia), Slenyto (pediatric PR, ASD/Smith-Magenis), Melatonin Neurim (generic Circadin).
Japan: Reclassified for OTC sale up to 2 mg (2026). Previously prescription-only.
Australia: Schedule 4 (prescription) at doses >2 mg.
Korea: Prescription or restricted. Not OTC.
Regulatory context: US OTC status reflects DSHEA classification (1994), not FDA safety/efficacy review. EU approach (authorized pharmaceutical for specific indications) is more evidence-based. Japan's 2026 reclassification follows growing recognition of safety at low doses.

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Claim	Relationship	Bradford Hill	Safety Flag	Key Weakness
Sleep onset reduction	DC	8/9	MON	Modest absolute effect (7–12 min); subjective benefit larger
Jet lag (eastward)	DC	7/9	--	Limited to eastward ≥5 TZ; timing-dependent
DSPS phase advance	DC	8/9	--	Requires specific timing compliance
Age-related insomnia	DC	7/9	MON	PR-specific; grogginess/fall risk in elderly
Pediatric ASD sleep	DC	7/9	MON	Long-term pubertal effects unclear
REM sleep behavior disorder	PC	6/9	MON	No large definitive RCT
Preoperative anxiety	PC	7/9	--	Limited clinical adoption despite evidence
Postop delirium prevention	PC	7/9	MON	3 MAs converge; ≥5 mg dose-response clear
Migraine prevention	UCC	5/9	--	Small RCTs; mechanism unclear
Blood pressure reduction	UCC	5/9	--	Non-dippers only; modest effect
Cardiometabolic biomarkers	BC	5/9	MON	Biomarker improvement ≠ clinical outcome
Cancer adjuvant	AHE	3/9	WARN	Hepatotoxicity at extreme doses; mostly preclinical
Depression (primary)	NE	1/9	--	Multiple RCTs show no benefit

Hype Check (Mode 1: Fallacy Radar)

"Natural hormone" framing: Appeal to nature. Melatonin's efficacy comes from receptor agonism, not "naturalness." Exogenous dosing is pharmacological intervention.
"Tolerance is a myth": Slightly overconfident. MT1/MT2 receptor tolerance is not demonstrated, but ~15–30% of users report diminishing subjective benefit — likely supraphysiological dosing or product quality variation, not pharmacological tolerance.
"Melatonin is a powerful antioxidant": Hasty generalization from preclinical to clinical. Strong in vitro/animal data does NOT translate to oral-dose clinical benefit. Antioxidant biomarker improvement ≠ health outcomes (vitamin E precedent).
High-dose longevity claims: Cherry-picked animal data extrapolated to human lifespan. No human longevity data exists.
Core sleep claims are solid. No significant fallacies in the 5/5 evidence base.

Evidence Gaps

Long-term (>2 year) safety data in adults and especially children
Pediatric pubertal timing effects (multi-year follow-up needed)
Head-to-head formulation comparisons (IR vs PR vs SL)
Optimal dose by CYP1A2 genotype (prospective validation needed)
Hard cardiovascular/metabolic endpoints (not just biomarkers)
Cancer adjuvant therapy definitive trials
Bone density as primary outcome (current data confounded)
Neonatal neuroprotection (Cochrane 2026: "very low certainty" — PMID: 41925053)
Why 15–30% are "non-responders" (MTNR1A/MTNR1B polymorphism?)

Bias Flags (Mode 4: First Principles)

Dose-response paradox: 0.3 mg ≈ 5 mg in efficacy, yet commercial products sell 5–10 mg. Reflects industry incentive (higher perceived value), not evidence.
Quality control gap: Erland 2017 found −83% to +478% label accuracy. This is the single biggest real-world risk — not the compound, but what's in the bottle.
Insulin sensitivity nuance: Lauritzen 2022 (PMID: 35619221) reported 11% ↓ in insulin sensitivity. But the 63-RCT MA (PMID: 41515249) found NO effect on HOMA-IR or HbA1c. Truth is likely population-specific (MTNR1B genotype matters).
Researcher independence: Most melatonin research is independently funded. Neurim Pharmaceuticals funds Circadin studies specifically. Low industry bias compared to prescription sleep aids.

Manipulation Flags (Mode 2: Manipulation Shield)

Industry marketing: Heavy dose inflation in commercial products (5–10 mg standard when 0.3–1 mg optimal). "Extra strength" 10 mg exploits consumer assumption more = better.
Influencer economics: Huberman's anti-melatonin stance aligns with promotion of Momentous supplements (mag threonate, apigenin). Life Extension promotes high-dose aligned with their product line. Financial context matters for both.
Counter-narrative manipulation: Prescription sleep aid companies benefit from melatonin's "too weak" narrative. "Why melatonin doesn't work" articles often redirect to branded alternatives (affiliate marketing pipeline).
Cui bono summary: If you take melatonin: supplement retailers win, you potentially win (cheap, safe sleep aid). If you don't: branded sleep stack companies win, prescription sleep aid companies win.
Red team highlight: Product quality is the single most concerning angle — you may not be getting what you paid for. Supply chain problem, not compound problem.

Decision Support (Mode 3: Clarity Compass)

General health utility: 8/10 — one of the most evidence-based, safest, cheapest supplements available
Opportunity cost: Very low. ~$3–15/month. Main cost: psychological crutch risk, minor timing hassle.
Verdict: ADD for sleep onset and circadian indications. WATCH LIST for delirium prevention (rapidly strengthening), atopic dermatitis, cardiometabolic biomarkers. SKIP for depression, cognitive enhancement, longevity, testosterone.
Conditions for ADD: Low dose (0.3–3 mg), correct timing relative to circadian phase, third-party tested product, glucose monitoring if T2DM.

Bottom Line

Melatonin is a genuine evidence-based compound for sleep onset and circadian disorders — one of the few supplements where the hype matches the science for its core indications. The "less is more" dosing paradigm is well-validated (0.3 mg ≈ 5 mg). Beyond sleep, the most exciting 2025–2026 development is delirium prevention (3 independent meta-analyses). Cardiometabolic biomarker improvements are real but may not translate to hard outcomes. The biggest real-world risk isn't the compound — it's product quality (−83% to +478% label accuracy). Buy USP/NSF verified. Dose 0.3–3 mg. Time it right. Ignore the high-dose hype.

Practical Notes

Brands & Product Selection

Third-party certified: Natrol (USP), NOW Foods, Pure Encapsulations, Thorne (NSF), Life Extension. EU: Circadin (Neurim Pharmaceuticals) — gold standard for prolonged-release.

Quality red flags: No third-party testing, "proprietary blend," unrealistic claims, no lot number/expiration, suspiciously low price. Erland 2017 (PMID: 27855744): 31 products tested, content varied −83% to +478%, 26% contained serotonin. Buy GMP-certified, third-party tested.

Storage & Handling

Store at room temperature (15–25°C), protected from direct sunlight and moisture. Do NOT store in bathroom medicine cabinet (humidity). Shelf life: 2–3 years unopened, 12–24 months opened. Melatonin degrades faster than most supplements with heat/light/moisture exposure.

Palatability & Compliance

IR tablets: tasteless if swallowed quickly; can crush for children (mix with applesauce). Sublingual: bitter, hold under tongue 5–10 min. Liquid: variable taste; mix with small amount of juice. Pick the form you'll stick with — compliance is the #1 determinant of supplement efficacy.

Exercise & Circadian Timing

Evening exercise (3–4 h before bed): compatible with melatonin supplementation
Late-night vigorous exercise: may counteract soporific effects
Morning/afternoon exercise: supports natural circadian rhythm, may enhance melatonin response
Athletes: avoid <8 h before competition. Not banned by WADA. 3 mg improves sleep but shows NO ergogenic effect (PMID: 41829968).
Cool bedroom (18–20°C) synergizes with melatonin's thermoregulatory effects.

Reference Ranges (Expected Biomarker Changes)

Biomarker	Young Adult	Middle-Aged	Elderly (65+)	Child (6–12)
Nighttime peak (pg/mL)	60–100	40–70	20–50	100–200
Daytime nadir (pg/mL)	<10	<10	<10	<10
Urinary 6-SMT (µg/night)	20–60	15–40	10–30	30–80

Endogenous production declines 30–50% with age. Peak secretion 2–4 AM. Melatonin cutoff 124.29 pg/mL proposed for osteoporosis screening in postmenopausal women (PMID: 41883562, AUC 0.942).

Cost

Formulation	Dose	$/day	$/month	Value
IR generic (best value)	3 mg	$0.10–0.20	$3–6	5/5
IR brand	3 mg	$0.30–0.50	$9–15	4/5
Prolonged-release	2–5 mg	$0.65–1.30	$20–40	3/5
Sublingual	3 mg	$0.50–1.00	$15–30	3/5
Liquid	3 mg	$0.50–1.00	$15–30	3/5

What We Don't Know

Optimal dose by CYP1A2 genotype (prospective validation absent)
Long-term (>2 year) effects on pubertal timing in children
Whether cardiometabolic biomarker improvements translate to hard cardiovascular outcomes
Why 15–30% of users are "non-responders" (MTNR1A/MTNR1B polymorphism? Receptor density?)
Definitive cancer adjuvant efficacy at high doses in humans
Whether neonatal neuroprotection actually works (Cochrane 2026: "very low certainty")
Exact mechanism of delirium prevention (despite robust clinical evidence)
Impact of product quality variation on real-world effectiveness
Long-term effects of chronic supraphysiological dosing (>10 mg/day for years)
Whether melatonin-microbiome modulation is clinically meaningful
Sex-specific dose optimization (most data in mixed populations)
Whether inhaled delivery (NCT06802913: 100µg vs oral 4 mg) will disrupt dosing paradigms

References

Systematic Reviews & Meta-Analyses

Ferracioli-Oda E et al. (2013). Meta-analysis: melatonin for primary sleep disorders. PLoS One 8(5):e63773. PMID: 23691095 — Landmark: −7.2 min SOL across 19 RCTs (N=1683)
Herxheimer A, Petrie KJ (2002). Melatonin for jet lag. Cochrane Database Syst Rev. PMID: 12076414 — 50–70% jet lag symptom reduction
Brzezinski A et al. (2005). Effects of exogenous melatonin on sleep. Sleep Med Rev 9(1):41-50. PMID: 15649737 — −4.0 min SOL in healthy adults
Buscemi N et al. (2006). Melatonin for secondary sleep disorders. BMJ 332:385-93. PMID: 16473858 — Efficacy for secondary insomnia, no serious AEs
Madsen BK et al. (2020). Melatonin for preoperative anxiety. Cochrane Database Syst Rev. PMID: 33319916 — 27 RCTs (N=2319): comparable to midazolam
Dose-response MA: melatonin on cardiometabolic risk (2025). Nutrients. PMID: 41515249 — 63 RCTs: ↓SBP, FBG, LDL, CRP; no effect on HOMA-IR/HbA1c
Melatonin/ramelteon for postop delirium (2026). J Clin Anesth. PMID: 41702325 — 16 RCTs (N=2115): RR 0.72; ≥5 mg: RR 0.52
BMJ NMA: drugs for postop delirium in elderly (2026). BMJ. PMID: 41690769
ICU delirium prevention (2026). Front Pharmacol. PMID: 41602948
Migraine prophylaxis MA (2026). Curr Pain Headache Rep. PMID: 41627537
Melatonin in CKD (2026). Front Nutr. PMID: 41727206 — Improved lipids, oxidative stress, sleep
Exercise performance + muscle damage (2026). Front Nutr. PMID: 41769636 — Timing-dependent
Menopausal BMD/QoL/sleep (2026). Front Nutr. PMID: 41693954 — Possible BMD improvement
Atopic dermatitis in children (2025). Front Med. PMID: 41647028 — Improved sleep + disease severity
Parkinson disease sleep (2026). J Sleep Res. PMID: 40588412
Cochrane: neonatal encephalopathy (2026). PMID: 41925053 — 4 RCTs, very low certainty
NMA: inpatient insomnia (2026). Sleep Med Rev. PMID: 41297371 — 29 RCTs framework
NMA: insomnia pharmacotherapies + FAERS (2025). Sleep Med. PMID: 41101148
European insomnia guideline (2023). PMID: 38016484 — Fast-release NOT recommended; PR considered

Landmark RCTs

Mundey K et al. (2005). Phase-dependent treatment of DSPS. Sleep 28(10):1271-8. PMID: 16295212 — 82 min phase advance at 6 PM dosing
Lemoine P et al. (2007). PR melatonin in insomnia 55+. J Sleep Res 16(4):372-80. PMID: 18036082 — 19% sleep quality improvement, no tolerance
Wade AG et al. (2010). 6-month PR melatonin. BMC Med 8:51. PMID: 20712869 — N=791: sustained efficacy, safe long-term
Gringras P et al. (2017). Pediatric PR melatonin in ASD. JAACAP 56(11):948-957. PMID: 29096778 — N=125: −51 min SOL
Melatonin in atopic dermatitis (2026). J Pineal Res. PMID: 41787942 — 10 mg: improved SCORAD, sleep, QoL
Ultra-low dose in female shift workers (2026). J Pineal Res. PMID: 41841489 — 0.3 mg: ↓climacteric symptoms 15.8%
No ergogenic effect in athletes (2026). Nutrients. PMID: 41829968 — 5–20 mg acute: no cycling benefit
Athletes sleep + HR stability (2026). Chronobiol Int. PMID: 41937599 — 3 mg × 5 nights

Safety & Pharmacology

Andersen LP et al. (2016). Safety of melatonin in humans. Clin Drug Investig 36(3):169-75. PMID: 26692007 — No deaths; AEs mild
Foley HM, Steel AE (2019). Adverse events with oral melatonin. Complement Ther Med 42:65-81. PMID: 30670284 — Drowsiness 5–15%, headache 5–8%
Besag FMC et al. (2019). Adverse events in sleep disorders. CNS Drugs 33(12):1167-1186. PMID: 31722088 — Low serious AE rate
Erland LAE, Saxena PK (2017). Melatonin content variability. JCSM 13(2):275-281. PMID: 27855744 — −83% to +478% of label
Harpsøe NG et al. (2015). Clinical pharmacokinetics. Eur J Clin Pharmacol 71(8):901-9. PMID: 26008214 — Bioavailability 9–33%, CYP1A2
Lane JM et al. (2016). CYP1A2 genetic variation. Sleep 39(10):1861-1870. PMID: 27450686 — 50–100% higher levels in slow metabolizers
MELATOMS-1 hepatotoxicity (2026). CNS Drugs. PMID: 41706381 — 300 mg/d: hepatotoxicity in polymedicated women
Apatinib-melatonin CYP1A2 interaction (2026). Chem Biol Interact. PMID: 41825755 — AUC ↑2.8×
CBD-melatonin PK interaction (2025). Pharmaceuticals. PMID: 41599679

Disease-Specific & Guidelines

Sack RL et al. (2007). AASM circadian rhythm disorders guideline. Sleep 30(11):1484-501. PMID: 18041481
Auger RR et al. (2015). AASM circadian rhythm update. JCSM 11(10):1199-236. PMID: 26414986
St Louis EK et al. (2017). RBD in Parkinson's. Mov Disord 32(5):645-658. PMID: 28516479 — 60–70% improvement
Reiter RJ et al. (2017). Melatonin anti-cancer mechanisms. Int J Mol Sci 18(4):843. PMID: 28420185 — High-dose preclinical
Andersen LP et al. (2016). Oral/IV pharmacokinetics. BMC Pharmacol Toxicol 17(1):8. PMID: 26979667
European pediatric melatonin guidance (2024). Eur J Pediatr. PMID: 38625388
Lauritzen ES et al. (2022). Melatonin + insulin sensitivity. Eur J Endocrinol. PMID: 35619221 — 11% ↓ insulin sensitivity in T2DM
AANAT polymorphisms + MDD (2026). Int J Dev Neurosci. PMID: 41789583 — G allele: ↑ MDD risk in young males
Melatonin-cortisol axis in aging (2026). Ageing Res Rev. PMID: 41730369
Serum melatonin + BMD postmenopausal (2026). Clin Med Insights. PMID: 41883562 — Cutoff 124.29 pg/mL (AUC 0.942)
Melatonin in IBD review (2023). PMID: 36535545